What Happened?
Ann Arbor, -based Millendo Promoted Jeffery Brinza as Chief Administrative Officer and General Counsel
About the Company
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing`s Syndrome (CS).
About the Person
Jeffery Brinza is Chief Administrative Officer and General Counsel at Millendo. Previously, Jeffery held various senior legal leadership roles in the industry.
Info Source
News
Short Profile